Knowles Corporation (NYSE:KN), a leading provider of advanced micro-acoustic microphones and speakers, precision devices, and audio processing technologies, reported a strong start to 2024 with financial results surpassing their guided range. In the first quarter of 2024, Knowles announced revenues of $196 million with earnings per share (EPS) at $0.20 and operational cash flow reaching $17 million.
The company's MedTech and specialty audio segment, as well as the Precision Device segment, both experienced significant revenue increases, with the latter benefiting from the acquisition of Cornell. Looking ahead, Knowles anticipates continued growth, projecting revenues between $199 million and $209 million for Q2 2024 and an adjusted EBIT margin of 14% to 16%.
Key Takeaways
- Knowles Corporation reported Q1 2024 revenue of $196 million, above expectations.
- Earnings per share (EPS) were reported at $0.20, with operational cash flow at $17 million.
- The MedTech and specialty audio segment saw a 26% revenue increase, and the Precision Device segment revenue grew by 38%.
- The Consumer MEMS Microphone segment experienced a 44% increase in revenue.
- For Q2 2024, Knowles forecasts revenues between $199 million and $209 million, with an adjusted EBIT margin range of 14% to 16%.
- The company is optimistic about the second half of the year and is exploring merger and acquisition opportunities.
Company Outlook
- Knowles expects double-digit revenue and adjusted EBIT growth in the Precision Device segment for the full year of 2024.
- Sequential revenue growth is anticipated from Q2 to Q3 and a further increase from Q3 to Q4, typically the largest quarter due to product launches.
- The company is progressing in its strategic alternatives process and expects a leverage ratio of less than 0.8 by year-end.
Bearish Highlights
- The company expects lower revenue for the year in the Cornell business but aims to meet EBITDA targets through synergies.
- Pricing in the rest of the Precision Devices business is projected to increase, albeit not as significantly as in the Cornell business.
Bullish Highlights
- Positive pricing trends are seen in the Precision Devices segment, especially in the Medtech and defense markets.
- The opportunity to raise prices in the distribution market is present, with distributors typically passing on price increases to customers.
- The company is cautiously more optimistic about the latter half of the year compared to three months ago.
Misses
- The company's revenue projections for 2024 are slightly lower than initially anticipated.
Q&A Highlights
- Knowles is focused on reducing exposure to the mobile business and expects sequential growth in the MSA segment in the latter half of the year.
- The pricing environment in the MSA segment is reported to be stable.
- In the Precision Devices segment, pricing is stabilizing for analog products, though MCUs face more pressure.
In conclusion, Knowles Corporation's Q1 2024 financial results demonstrate a robust start to the year, with significant growth in key segments and a positive outlook for the upcoming quarters. The company's strategic moves, including the acquisition of Cornell and focus on high-margin markets, position it well for continued success and opportunities for expansion through mergers and acquisitions.
InvestingPro Insights
Knowles Corporation's strong start to 2024 has been reflected in several key financial metrics. The company's market capitalization currently stands at $1.42 billion, showcasing its substantial presence in the industry. Notably, Knowles is trading at a P/E ratio of 20.19, which adjusts to an even more attractive 18.17 when considering the last twelve months as of Q1 2024. This valuation comes in light of the company's revenue growth of 7.36% over the same period, indicating a healthy expansion in its business operations.
InvestingPro Tips highlight the company's share buyback initiative, which is often a sign of management's confidence in the company's value. Moreover, Knowles is recognized for trading at a low P/E ratio relative to near-term earnings growth, which might attract investors looking for value stocks with growth potential. These factors, combined with the company's low price volatility, could present a compelling case for investors considering Knowles Corporation.
Investors can explore additional InvestingPro Tips for Knowles Corporation, which include insights such as the company's liquidity position, profitability forecasts, and dividend policies. There are currently 6 more tips listed on InvestingPro for Knowles, which can provide a deeper understanding of the company's financial health and market position.
To gain access to these valuable insights, investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
With the company's next earnings date set for July 31, 2024, investors will be keenly watching whether Knowles can maintain its positive trajectory and continue to deliver on its financial promises.
Full transcript - Knowles Cor (KN) Q1 2024:
Operator: Thank you for standing by, and welcome to the First Quarter 2024 Knowles Corporation Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. [Operator Instructions] Thank you. I would now like to turn the call over to Sarah Cook. Please go ahead.
Sarah Cook: Thank you, and welcome to our Q1 2024 earnings call. I'm Sarah Cook, Vice President of Investor Relations. And presenting with me today are Jeffrey Niew, our President and CEO; and John Anderson, our Senior Vice President and CFO. Our call today will include remarks about future expectations, plans and prospects for Knowles, which constitute forward-looking statements for purposes of Safe Harbor provisions under applicable federal securities laws. Forward-looking statements in this call will include comments about demand for company products, anticipated trends in company's sales, expenses and profits, and involve a number of risks and uncertainties that could cause actual results to differ materially from current expectations. The company urges investors to review the risks and uncertainties in the company's SEC filings, including, but not limited to, the annual report on Form 10-K for the fiscal year ended December 31, 2023, periodic reports filed from time-to-time with the SEC, and risks and uncertainties identified in today's earnings release. All forward-looking statements are made as of the date of this call, and Knowles disclaims any duty to update such statements, except as required by law. In addition, pursuant to Reg G, any non-GAAP financial measures referenced during today's conference call can be found in our press release posted on our website at knowles.com, and in our current report on Form 8-K filed today with the SEC, including a reconciliation to the most directly comparable GAAP measures. All financial references on this call will be on a non-GAAP continuing operations basis unless otherwise indicated. We've made selected financial information available in webcast slides, which can be found in the Investor Relations section of our website. With that, let me turn the call over to Jeff who will provide details on our results. Jeff?
Jeffrey Niew: Thanks Sarah and thanks to all of you for joining us today. I'm very pleased with the start of 2024 as our first quarter results showed the potential of our businesses to expand EBIT margins and drive strong free cash flow. We are continuing to our transformation to focus on high-growth end markets where we have differentiated solutions and our Q1 financial performance is evidence that our strategy is working. In the first quarter, we delivered revenue of $196 million above the midpoint of our guided range, EPS of $0.20 at the high end of our guided range and cash from operations of $17 million, which exceeded the high end of our guided range. Turning to segment results, MedTech and specialty audio revenue was up 26% with over 90% adjusted EBIT growth versus the same period a year ago. The end markets for our hearing health products remain robust as market dynamics such as aging populations, expansion of middle class globally and improved hearing aid penetration, all remain favorable. Second, our operational excellence continues to produce strong margin performance. This coupled with our success in new product adoption is driving revenue growth with expanding EBIT margins and cash flow for 2024. Precision Device revenue was up 38% from a year ago driven by the acquisition of Cornell. As we expected the end market challenges we experienced in the back half of 2023 continued into the first half of 2024 as inventory levels within distribution and the industrial end markets remain high. We remain focused on design activity, which continues to be robust in defense, life sciences, industrial and EV and positions us well for future growth. We continue to be excited about the performance, synergistic opportunities and total available market expansion Cornell brings to the PD segment. With the beginning of an anticipated recovery in the second half of the year and the addition of Cornell, we expect to see double digit revenue and adjusted EBIT growth within this segment in 2024. Before moving to the results for the consumer mems microphone business, I will provide some brief commentary on the status of the strategic alternatives process that we announced last year. We are taking into consideration all the stakeholders from customers to suppliers and shareholders to employees, and I believe we are progressing to a conclusion. From an operational standpoint, CMM's financial result in the quarter were solid. Revenue was up 44% from the same period a year ago, as the business has returned to more stabilized levels. We've expanded our mobile and ear share and expecting to continue to see revenue growth in the second quarter and for the full year 2024, as compared to 2023 levels. In closing, we expect to continue to generate robust cash from operations in Q2 and the remainder of 2024 despite excess share inventory negatively impacting demand within our PD segment. Our cash generation and strong balance sheet will allow us to explore acquisition opportunity, buy back shares and keep our debt at manageable levels. I am pleased with the financial performance to date in 2024 and I'm excited about the opportunities we have ahead of us. We are confident in our ability to deliver shareholder value, as we continue to drive operational excellence, execute on design wins in all three segments and expand our share across our businesses. Now, let me turn the call over to John to detail our quarter results and provide some guidance.
John Anderson: Thanks, Jeff. We reported first quarter revenues of $196 million above the midpoint of guidance and up 36% from the year ago period, driven by double digit growth in all three segments. EPS was $0.20 in the quarter at the high end of our guidance range and $0.15 above the year-ago period, driven by increased gross profit associated with higher shipment volume, partially offset by higher interest expense. In the MedTech and specialty audio segment, revenue was $57 million, up 26% versus the first quarter of 2023 and increased demand in the hearing health market, as customer inventories have returned to normal levels. Gross margins were 54.8%, up 1,130 basis points versus the prior year driven by improved factory performance and favorable product mix. The precision devices segment delivered revenues of $74 million, up 38% from the year ago period driven by the acquisition of Cornell, partially offset by lower shipments into the distribution and industrial end markets as channel and customer inventory levels remain elevated. Gross margins were 36.1%, down 1,100 basis points from prior year levels due to lower factory capacity utilization and the acquisition of Cornell. Consumer MEMS microphone revenues of $65 million were up 44% versus the year ago period, due to increased consumer demand and share gains in mobile, ear and compute markets. Gross margins were 26.2%, 450 basis points above Q1 2023 on improved factory capacity utilization, partially offset by lower pricing. On a total company basis, R&D expense in the quarter was $16.7 million flat compared to the prior year. SG&A expenses were $32 million, $5 million higher than prior year levels, driven by the acquisition of Cornell, partially offset by the benefits of prior restructuring actions taken in both the Precision Devices and CMM segments. Interest expense was up $4 million versus the prior year due to the acquisition of Cornell in the fourth quarter of 2023. Now, I'll turn to our balance sheet and cash flow. In the first quarter, we generated $17 million in cash from operating activities above the high end of our guidance, driven by higher customer collections and lower than expected inventory levels. Capital spending was $3 million. We ended the quarter with cash and cash equivalents of $122 million. We exited the first quarter of 2024 with $293 million of debt, which includes $180 million of borrowings under our revolving credit facility and an interest free seller note which was issued in connection with the Cornell acquisition. Lastly, our net leverage ratio based on trailing 12-months EBITDA was 1.1 times. Moving to our guidance. For the second quarter of 2024, revenues are expected to be between $199 million and $209 million, up 18% versus the year ago period, driven primarily by the acquisition of Cornell. R&D expenses are expected to be between $16 million and $18 million and selling and administrative expenses are expected to be within the range of $29 million to $31 million, up from prior year due to the Cornell acquisition. We're projecting adjusted EBIT margin for the quarter to be within a range of 14% to 16%. We're forecasting interest expense in Q2 to be approximately $5 million, which includes $2 million of non-cash imputed interest. And we expect an effective tax rate of 14% to 16% for both the quarter and full year 2024. We're projecting EPS to be within a range of $0.22 to $0.26 per share. This assumes weighted average shares outstanding during the quarter of $93 million on a fully diluted basis. We're projecting cash from operations to be within a range of $20 million to $30 million and capital spending is expected to be $5 million. I will now turn the call back over to the operator for the questions-and-answers portion of the call. Operator?
Operator: Thank you. We will now begin the question-and-answer session. [Operator Instructions] Your first question comes from the line of Christopher Rolland of Susquehanna. Your line is now open.
Christopher Rolland: Thanks for the question. I guess for my first one, if you guys could dig into the profile of that back half recovery like what kind of sequential should we be expecting in our double-digit variety or kind of the single-digit variety and Yes. Like any other color by segment would for of course, Q2. But the profile for the rest of the year would be great as well if you can give that.
Jeffrey Niew: Yes, Chris, thanks for the question. Good question. So let me just kind of break it out by segment and then I'll kind of summarize it again. But first on the PD segment on. I think what we're expecting now is we had of Q1 to Q2, we are seeing sequential growth in the PD segment. We expect to see sequential growth again in Q3 and in Q4 right now we expect that in just a little color around that. I think we're probably a little bit of more I would say a cautious now on industrial and distribution in the rate of arising, it's still going up sequentially but not quite as much. And I would say more of our OEM customers, bigger OEM customers net new defense, we see more growth there. And so your overall for PD again, we're going to see I would say pretty decent sequential growth in the back half of the year but probably more heavily weighted towards the fourth quarter. Second in MSA, I think they're hitting on all cylinders. They're doing very well. The market's very strong, our execution, our new products and we're doing very well in this market. And I just would remind you is Q4 is typically our largest quarter. There's a big you're hearing a launch of products in Q3, which kind of drives revenue in Q4. So we would expect that while we'll see some sequential growth going forward and it's really going to come in Q4. And then lastly I think CMM, you normally seasonally higher in the back half than the front half. I would think we're cautiously more optimistic about the back half than we say we're three months ago. And so I think overall, I think when I look at that, I'd say again, probably a little bit more heavily weighted to the fourth quarter but we do expect to have nice sequential growth from Q2 to Q3 and then even a little bit more from Q3 to Q4.
Christopher Rolland: Thank you so much, Jeff. That's so helpful. The second one is around the appetite for the CMM business or progress there. And then any update more broadly you might have on M&A?
Jeffrey Niew: Sure. Let me take the first and second question first. I think, if you look at our leverage ratio, as John mentioned….
John Anderson: Just a touch over one.
Jeffrey Niew: Just a touch over one. If you look out through the full year with the cash we expect to generate I think we'll probably be something south of 0.8 leverage ratio by the end of the year. And so with that kind of leverage ratio, we're looking in the marketplace. Of course we're going to be super disciplined in what we do kind of like how we know again I bring up Cornell. We are very pleased with this acquisition. I continue to feel very good that despite some of the challenges in industrial and distribution, it's still performing to the levels that we kind of announced when the deal was announced. And so I think we're very excited to look for other acquisition opportunities and hopefully, they'll build little ones will come along. That makes sense relative to advancing kind of our strategic positioning.
John Anderson: If I could just add too. I mean, Jeff mentioned here we do expect our leverage to come down a bit over 2024. In addition, we expect to continue to repurchase shares and we think our stock price is undervalued. So it will be a combination of share buybacks and paydown of debt.
Jeffrey Niew: As far as the amount, I think I don't have too much more to say. You know maybe I'll just kind of like say it might be my own non-scripted words, but there's a lot of stakeholders in play and place here. And I think we've kind of been very clear that that you'll obviously post whatever happens with CMM. We do still have our MSA business which will be selling mems microphones. And so I think I kind of said our employees are our -- I'm saying to our shareholders, I say to our suppliers. Yeah, I think it's -- we're taking a little bit more time than probably people would have bought. But I think we're being very thoughtful about what we do. And but I do think we're getting closer to a conclusion. We are progressing towards a conclusion. And so I think you could take for that what that means. But I think we're kind of narrowing in on what the direction we're going to go.
Christopher Rolland: Great update. Thanks guys.
Operator: Your next question comes from the line of Bob Labick of CJS Securities. Your line is open.
Pete Lukas: Yes. Hi, it's Pete Lukas for Bob. You covered a lot and answered a lot of my questions. Just one here for you, just an update on the integration and synergies of CD, and how is pricing power, and do you still think margins can be increased?
Jeffrey Niew: Yeah. That's a good question, very good question. I mean, I think when we announced the deal, we really focused in on cost synergies that we were going to do and we're on track to deliver those cost synergies that we had kind of laid out at the beginning.
John Anderson: It's a 4 million annual cost synergies by the end of year three.
Jeffrey Niew: We're on track to deliver those. I would sit there and say beyond that there are going to be what we call revenue synergies, but not revisited is just going out and getting more sales. But we did think there was a pricing opportunity. I would say we are running ahead of what we expected with really starting to take hold more in the back half of the year than in the front half, you know, with contracts in inventory some of these times you give price increases and it takes a quarter or two to actually start delivering of product at those new price levels. But we are expecting that we have quite nice pricing increases. And our expectations is that when we bought this business, we were pretty clear it was in the low 30% in terms of gross margin that we think that that will be approaching like over 35% probably approaching 40% exiting the year. And so it's a combination of cost synergies as well as pricing. And I think as we looked at 2025 obviously, we didn't get all the pricing in this year because obviously it rolls through the year. If there's that you'll even with not doing another price increase, some of this will roll over into future price increases during the first two three quarters of next year. So I think we're pretty excited about the opportunities in terms of synergy. And lastly, I just want to just look for one more piece on Cornell, I think you were really starting to understand a little bit better about some of the things that they do. They're very unique in terms of products. So there's going to be some opportunities. I think we'll probably talk about at an Investor Day later this year in some of the new markets that we probably will go after. But I would also say is the strength that they have in distribution with our distribution partners like Arrow and TTI is a great opportunity as for our legacy PT business to start getting more business in distribution. So obviously, that's not a short term thing like this year. But I think overall I think I think we couldn't be quite frankly more pleased with this same kind of industrial distribution inventory issues that most people have been dealing with.
Pete Lukas: Very helpful. Thanks.
Operator: Your next question comes from the line of Anthony Stoss from Craig-Hallum Capital Group. Your line is open.
Anthony Stoss: Good afternoon, guys. Nice execution, Jeff. I'm curious, if you wouldn't mind sharing your view on either changes in your competitors in terms of their go-to-market or pricing within each of the segments? And also, it's nice to see PD up expected to be up each quarter sequentially. Can the same be said for the medtech group?
Jeffrey Niew: Well, again, I would sit there and say for the full year, MSA will be up for the full year and growing in kind of that rate that we've kind of talked about and that 3% to 5% range. And so it does tend to be, as I kind of said on an earlier question, a little bit more heavily weighted in terms of seasonally to Q4, but I don't have any big issues on this because we see this every year. You can see Q4 always being the heaviest year within the MSA segment, driven by the product launches of our customers. So that's what I'd say about, I would say. As far as the competitive environment, let me cover it by segment. In the PV segment, no big changes really I think we have a lot of sole-source positions. I would just say the one thing, obviously, people are hearing is EV is slower than probably what we'd help for. But as we kind of see a recovery, I think the one thing I'm very encouraged about in the PD is that we're seeing increasing gross margins throughout the year, which is showing that we don't have to get back to 2022 levels in order to really get back to gross margins we saw back then. And so I think, there's some pricing in there. There's some productivity. There's obviously revenue growth and where we get the revenue growth helps us with capacity utilization. MSA, I'd say, the pricing environment is stable. That's what I would just say, there really hasn't any change in the competitive environment over the last year or so. And I think in the CMM business, I think -- the thing that we just keep saying, which is kind of like in the last couple of quarters, which is mobile is a tough business. And we are trying to kind of reduce our exposure over time to mobile. I think over the years, at one point, our company was 35% mobile. Last year, it was around 15%. I would say, we would expect it to be sub-15% this year. As we continue to try and diversify the total company revenue kind of away from the mobile environment.
Anthony Stoss: Got it. Thanks for that Jeff. And you guys are definitely outperforming your other mobile peers in chip plant. So congrats on that. That's all my questions. Thank you.
Jeffrey Niew: Thanks, Anthony.
Operator: [Operator Instructions] Your next question comes from Tristan Gerra of Baird. Your line is now open.
Tristan Gerra: Hi. Good afternoon. You've mentioned that most of the year-over-year growth embedded in your Q2 revenue guidance would be coming from Cornell. So I'm guessing high 20s, maybe $30 million in revenue in the quarter. Can you remind us of the seasonality of that business? How does this tie to a full year revenue number. I'm guessing that we're probably going to be below the $140 million plus that you've talked about before, given the macro headwind for corner, but just wanted to kind of get an update on that.
Jeffrey Niew: Yeah. I wouldn't say there's a tremendous amount of seasonality, Tristan, in this business. But we are -- based on bookings, we are expecting to see sequential growth in Q3 and then sequential growth in Q4 again. And so what I would say is we had said $140 million in revenue and $26 million in EBITDA. We're probably going to be a touch short of the $140 million I would say right now, if you were between $135 million and $140 million in probably for the year, but I think at that level, lower revenue will still hit the EBITDA number based on the synergies we've recognized. So I think we feel pretty good about that.
John Anderson: The other thing I'd add, Tristan, in terms of the Cornell, we really are excited about the cash flow generation ability of that business even as Jeff said, slightly lower revenue plan for 2024, the business is going to generate more cash flow than we envisioned in our model.
Tristan Gerra: That's great. And then you talked about the positive pricing that you see in Precision Devices help us reconcile this with the overall environment that we're seeing pricing stabilizing, meaning kind of returning to kind of low single-digit declines. We see that in analog, we're seeing more pressure in MCUs up. So what's driving the pricing that you're able to implement you know in PD? And if you could talk about lead times and supply demand dynamics that you see in that space industry-wide actually. So, we cannot get a sense of what the landscape is with pricing going forward.
Jeffrey Niew: Yes. So here's, I kind of describe it. If you think about the markets that we really in Precision Devices are focused on, Medtech, defense, industrial and distribution. Let me break those out, in Medtech though in defense, we have a lot of sole-source positions where we have unique offering. This has kind of been the strategy all along, where we're trying to move in a direction where we can provide differentiated products in these spaces, and then have some amount of pricing power going forward. And so we feel pretty good about those end markets. Now distributions a little bit different of an animal, just as I've described, but here's what I'd say, I think we've talked about Cornell. Cornell shipped in 20 private -- 12 months prior to us owning it. They shipped to 30,000 unique customers. And a lot of those are through distribution, a lot of them are customers that are sub 50K [ph] form. We kind of see that as an opportunity when we bought the business to say, I'm just making these numbers up now, but if you raise prices by 5% on a $50,000 a year customer, you're raising prices by $2,500. And so we see that the value of that distribution market because what happens typically, I've seen in distribution is, if we raise prices to the smaller customers through distribution, the distributor just passes those on. And so, the underlying demand is going to be what it's going to be, right. Obviously, there are some challenges underlying demands and when it comes back, it will be better for it. And so overall, when I see this is the pricing environment for us, because of our position in Medtech and defense coupled with distribution. We're not facing quite the kind of things that some of the things people our more commoditized our products are.
Tristan Gerra: Okay. That's great. So it sounds like the pricing optimization opportunity is really on the Cornell side. Outside of that, would you say that pricing is stable in the rest of your Precision Device business?
Jeffrey Niew: No, I would say that prices are probably still going to be up, in the rest of Precision Devices. But here's the differences. What we've done in Cornell in terms of pricing this year under the ownership, we went to the same I think three four years ago, in overall Precision Devices. So, the amount we're getting in any given year with the legacy PD, is not going to be as large, as the first what we saw in the Cornell opportunity. So, I think from our perspective is we're still getting some price this year in the legacy PD, but the Cornell, it was an untapped opportunity that we've figured out and we're taking advantage of.
Tristan Gerra: Great. Thank you very much.
Operator: [Operator Instructions] There are no further questions at this time. This concludes today's call. Thank you all for joining. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.